← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Allient revenue rose 4.6% to $554.5M, net income rose 67.4%, and free cash flow rose 54.5%.
The read at a glance✓ Audited against SEC data
- Business mix — Precision controlled-motion systemsNote
- Revenue — Revenue rose 4.6% to $554.5MOK
- Profitability — Net income rose to $22.0MOK
- Cash — Free cash flow rose 54.5%OK
- Balance sheet — Debt fell 19.5%; equity rose 13.8%OK
- Insiders — 1 buy / 2 sellsNote
- Accounting — Altman-Z grey; EQ safeNote
Business
Allient designs, makes, and sells precision and specialty controlled-motion components and systems for industrial, vehicle, medical, and aerospace and defense markets.
Where the revenue comes from
Fiscal 2025, as ALLIENT INC reports it. History and quarterly detail are in the app.
- Industrial And Electronics$268.4M
- Vehicle$97.0M
- Medical$81.7M
- Aerospace And Defense$81.3M
- Distribution And Other Target Market$26.0M
Leadership changes
From ALLIENT INC's own filings, the day they're filed.
- Robert P. Maida · President · departureeff. 2023-09-30
- Other Provisions · departure
- Involuntary Termination Without Cause · departure
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-05-11
- 10-Q · Quarterly report2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-03-26
- 10-K · Annual report2026-03-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALLIENT INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.